Brendan M Weiss1, Joseph Hebreo2, Daniel V Cordaro2, Mark J Roschewski2, Thomas P Baker2, Kevin C Abbott2, Stephen W Olson2. 1. Brendan M. Weiss, University of Pennsylvania, Philadelphia, PA; Joseph Hebreo, Naval Medical Center San Diego, San Diego, CA; Daniel V. Cordaro, Mark J. Roschewski, Thomas Baker, Kevin C. Abbott, and Stephen W. Olson, Walter Reed National Military Medical Center, Bethesda, MD. brendan.weiss@uphs.upenn.edu. 2. Brendan M. Weiss, University of Pennsylvania, Philadelphia, PA; Joseph Hebreo, Naval Medical Center San Diego, San Diego, CA; Daniel V. Cordaro, Mark J. Roschewski, Thomas Baker, Kevin C. Abbott, and Stephen W. Olson, Walter Reed National Military Medical Center, Bethesda, MD.
Abstract
PURPOSE: Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. PATIENTS AND METHODS: We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. RESULTS: An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/L; P < .001), 4 to 11 years (65.1 v 2.2 mg/L; P < .001), and more than 11 years (4.5 v 0.4 mg/L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). CONCLUSION: Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years.
PURPOSE:Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. PATIENTS AND METHODS: We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. RESULTS: An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/L; P < .001), 4 to 11 years (65.1 v 2.2 mg/L; P < .001), and more than 11 years (4.5 v 0.4 mg/L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). CONCLUSION: Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years.
Authors: Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar Journal: Lancet Date: 2010-05-15 Impact factor: 79.321
Authors: Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; Tow Tan; Shirshendu Sinha; Nelson Leung; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz Journal: Am J Hematol Date: 2011-02-15 Impact factor: 10.047
Authors: Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Tilmann Bochtler; Ute Hegenbart; Friedrich W Cremer; Christiane Heiss; Axel Benner; Dirk Hose; Marion Moos; Jelena Bila; Claus R Bartram; Anthony D Ho; Hartmut Goldschmidt; Anna Jauch; Stefan O Schonland Journal: Blood Date: 2008-02-27 Impact factor: 22.113
Authors: A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: Emily B Martin; Angela Williams; Craig Wooliver; R Eric Heidel; Sarah Adams; John Dunlap; Marina Ramirez-Alvarado; Luis M Blancas-Mejia; Ronald H Lands; Stephen J Kennel; Jonathan S Wall Journal: PLoS One Date: 2017-03-28 Impact factor: 3.240